ASX ANNOUNCEMENT

21 March 2023

PRESENTATION AT NWR VIRTUAL HEALTHCARE CONFERENCE

BRISBANE, Australia and **MINNEAPOLIS, USA**, Anteris Technologies Ltd (**Anteris** or the **Company**) (ASX: AVR) is pleased to provide the attached presentation that Mr Wayne Paterson, Chief Executive Officer will present at the NWR Virtual Healthcare Conference on Tuesday 21 March 2023.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link: http://bit.ly/3Lzb5Xg

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor contact
Deanne Curry
GRACosway
E: investors@anteristech.com
M: +61 414 388 997

Media contact
Nick Howe
GRACosway
nhowe@gracosway.com.au
M: +61 407 183 221

www.anteristech.com
Twitter: @AnterisTech
Facebook: www.facebook.com/AnterisTech
LinkedIn: https://www.linkedin.com/company/anteristech

ANTERIS

Investor Presentation

March 2023

A late-stage development company that has proven clinical results

www.anteristech.com | Follow us @anteristech

ADAPT for life

Disclaimer

IMPORTANT NOTICE AND DISCLAIMER

Summary information

This presentation has been prepared by Anteris Technologies Limited (the "Company"). It is a presentation of general background information in summary form about the Company's activities current at the date of this presentation. The information does not purport to be complete, comprehensive or to comprise all the information which a potential investor may require in order to determine whether to deal in the Company's securities, nor does it contain all the information which would be required in a disclosure document prepared in accordance with the Corporations Act 2001 (Cth) (the "Corporations Act"). It is to be read in conjunction with the Company's other announcements released to the Australian Securities Exchange ("ASX") (available at www.asx.com.au).

No offer, advice or recommendation

This presentation is for information purposes only and should not be read or understood as an offer, invitation, solicitation, inducement or recommendation to subscribe, buy or sell securities in the Company in any jurisdiction. This presentation will not form any part of any contract or commitment for the acquisition of the Company's securities. This presentation is not a prospectus or other offering document under Australian law or any law. It will not be lodged with the Australian Securities and Investments Commission ("ASIC").
Nothing contained in this presentation constitutes financial product, investment, legal, tax or other advice. It does not take into account the investment objectives, financial situation or needs of any particular investor. You should consider the appropriateness of the information in this presentation having regard to your own investment objectives, financial situation and needs and with your own professional advice, when deciding if an investment is appropriate.

Not for distribution or release in the United States

This presentation may not be distributed or released in the United States. This presentation and the information contained herein does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction in which such offer would be illegal. Any securities described in this presentation have not been, and will not be, registered under the U.S. Securities Act of 1933 (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States unless the securities have been registered under the Securities Act (which the Company has no obligation to do or to procure) or are offered or sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable securities laws of any state or other jurisdiction of the United States.
The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions. Refer to the "International offer restrictions" on slides [x] to [x] of this presentation for more information.

Disclaimer (Continued)

Forward-looking statements

This presentation contains forward looking statements Forward-looking statements can generally be identified by use of words such as “may”, “should”, “could”, “foresee”, “plan”, “aim”, “will”, “expect”, “intend”, “project”, “estimate”, “anticipate”, “believe”, “forecast”, "target", "outlook", "guidance" or “continue” or similar expressions. Forward looking statements include statements about the future financial or operating performance of the Company and its related bodies corporate, statements about the Company’s current and future clinical studies, statements about the obtention and timing of regulatory approvals for the Company's products under development, statements about the Company's plans, strategies and objectives, including regarding the commercialization of its products, and statements about the industry and the markets in which the Company operates and statement about the effect of the offer described herein and proposed use of proceeds. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant technical, business, economic, competitive, political and social risks, contingencies and uncertainties.

These forward-looking statements are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company and its related bodies corporate and affiliates (and each of their respective directors, securityholders, officers, employees, partners, agents, advisers and management), and could cause actual results, performance or achievements to be materially
different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements or any projections and assumptions on which those statements are based. Refer to the ‘Key risks’ on slides 38 – 44 of this presentation for a summary of certain risk factors that may affect the Company.

Forward-looking statements are provided as a general guide only and should not be relied on as an indication or guarantee of future performance.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intent or obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. All forward-looking statements made in this presentation are qualified by the foregoing cautionary statements. Investors are cautioned that forward-looking statements are not predictions or guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Financial data

All currency amounts are in Australian Dollars ("$") unless otherwise stated.

Investors should be aware that financial data in this presentation include "non-IFRS financial information" under ASIC Regulatory Guide 230 "Disclosing non-IFRS financial information" published by ASIC and also "non-GAAP financial measures" within the meaning of Regulation G under the U.S. Securities Exchange Act of 1934, and are not recognised under Australian Accounting Standards (“AAS”) and International Financial Reporting Standards (“IFRS”). The disclosure of non-GAAP financial measures in the manner included in this presentation may not be permissible in a registration statement under the Securities Act. The non-IFRS financial information/non-GAAP financial measures in this presentation include EBITDA presented on slide 30 Non-IFRS financial information/non-GAAP financial measures do not have a standardised meaning prescribed by AAS or
IFRS and may therefore not be comparable to similarly titled measures presented by other entities and should not be construed as an alternative to other financial measures determined in accordance with AAS or IFRS.

Although the Company believes this non-IFRS financial information/non-GAAP financial measures provides useful information to users in measuring the financial performance and condition of the Company, investors are cautioned not to place undue reliance on any non-IFRS financial information/non-GAAP financial measures included in this presentation.

The financial information in this presentation is presented in an abbreviated form insofar as it does not include all the disclosures required by the AAS and other mandatory professional reporting requirements applicable to general purpose financial reports prepared in accordance with the Corporations Act.

A number of figures, amounts, percentages estimates, calculations of value and other fractions used in this presentation are subject to the effect of rounding.

Disclaimer (Continued)

Past performance

Past performance is given for illustrative purposes only. It should not be relied on and is not indicative of future performance, including future security prices.

Market data

Certain market and industry data used in this presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither the Company nor its representatives or its advisers have independently verified any market data ("Market Data") or industry data provided by third parties or industry or general publications.

Market Data is provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. The Market Data may assume the success of the Company's business strategies, the success of which may not be realised within the period for which the Market Data has been prepared, or at all.

No guarantee, representation or warranty, express or implied, is made as to the accuracy, likelihood or achievement or reasonableness of any Market Data. Except as required by applicable laws, rules or regulations, none of the Issuer, its representatives or advisers intends to, or undertakes to, or assumes any obligation to, provide any additional information or revise the Market Data, whether as a result of a change in expectations or assumptions, new information, future events,
results or circumstances.

Anteris has created a new class of product to treat a fatal disease

Anteris has developed and combined 3 distinct medical technologies that address current unmet medical needs

- Anteris™ is competing in a **USD $10bn market**
- **Clinical studies underway are demonstrating superiority**
- **ADAPT®** is the proprietary anti-calcification treatment platform technology on which our structural heart products are built
- **ADAPT®** is the only anti-calcification treatment to demonstrate zero calcification in humans over 10 years
- **ADAPT®** has properties that are critical to longer lasting aortic valves
- **ADAPT®** has been used in over **35,000** patients globally and is FDA approved
- **DurAVR™**, built with ADAPT® technology, is a novel and highly durable biomimetic aortic valve for the treatment of aortic stenosis
- **ComaSUR™** is a proprietary delivery system/catheter that is used to place DurAVR™ in patients



Company Milestones



Anteris Management Team

Wayne Paterson

Chief Executive Officer & Managing Director

- Joined Anteris as CEO in 2018 after previously serving as Chairman of the Board since 2016
- Senior positions at Merck KGaA, including President of Europe, Canada and Australia
- President of Emerging Markets, President of Japan and Global Head of Cardiovascular Medicine
- MBA from the University of Southern Queensland and a degree in Business Studies from the Queensland University of Technology

Today's Presenter

Matthew McDonnell

Chief Financial Officer

- Joined Anteris as CFO in November 2018
- 29 years of experience in Finance
- Previously served for 10 years as a partner at KPMG
- Bachelor of Economics, is an Associate of Chartered Accountants in Australia and New Zealand, and a Fellow of the Financial Services Institute of Australasia

Christopher Meduri, MD, MPH

Chief Medical Officer

- Joined Anteris as CMO in August 2021 after serving on medical advisory board since 2017
- Practicing Interventional Cardiologist at Karolinska Institute in Stockholm, Sweden. Previously the Bernie Marcus Chief of Structural Valve Disease at Piedmont Hospital in Atlanta, Georgia
- Global Principal Investigator or steering committee member of numerous structural heart trials. Performed over 2,000 TAVR procedures
- Internship and residency at Duke University. General, Interventional and Structural fellowships at Harvard Medical School's Beth Israel Deaconess Medical Center
- Master in public health from Harvard School of Public Health

David St. Denis

Chief Operating Officer

- Joined Anteris as COO in July 2017
- 20+ years of experience in biopharmaceutical and medical device industries
- B.S. from the University of Connecticut, a Master of Arts from Boston University and an MBA in Global Management and International Marketing from Babson College – Franklin W. Olin Graduate School of Business

Anteris has developed a first in class valve to treat Aortic stenosis

Severe Aortic stenosis is fatal if left untreated in 50% of patients over 2 years

Surgical Aortic Valve Replacement (SAVR)



1 in 8 people over 75 have Aortic Stenosis



Transcatheter Aortic Valve Replacement (TAVR)



TAVR market remains significantly under penetrated after a decade

AS Patient population underpenetrated

~1 of 10 Severe AS treated today



TAVR Market expected to nearly double by 2028



Source: population risk stratification from STS data base with 140k patients undergoing surgery, TAVR penetration estimates from SVB Leering analyst physician survey April '22, Market projections from Truist securities analyst report

TAVR Will Account for 87% of AVR's by 2028

U.S. TAVR / Surgical Aortic Stenosis Procedures 2021



U.S. TAVR / Surgical Aortic Stenosis Procedures 2028



Source: Millennium Research Group Report: Medtech 360 Heart Valve Devices | Market Insights | US | 2021.

Yesterday's TAVR's Were Not Imagined For Today's Patients

Designed by physicians from the start, this new class of product is designed to meet the needs of todays patients

"Patients need a safe alternative to open heart surgery"

1st and 2nd Generation TAVRs

~85yrs

2011 – 2013 average patient age was 84(1)

"Patients need a valve that restores an active lifestyle for the rest of their life"

3rd Generation DurAVR™

~65yrs

From 2019 the average patient age is 73 and declining(2)

DurAVR™ was designed for younger and more active patients

Sources:
(1) STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. J Am Coll Cardiol (2020);76:2492-2516.
(2) N Engl J Med 2019; 380:1695-1705.
DurAVR™ THV IS NOT AVAILABLE FOR SALE, FOR CLINICAL INVESTIGATIONAL USE ONLY.


WHY IT MATTERS

Patients Need New Solutions that Last Longer and Work Better

By taking a Patient and Physician centric approach we have developed advanced treatments for aortic stenosis

Younger patients now eligible

Guidelines
TAVR as class for ages 65-80

Indications:
- **Moderate**
- **Asymptomatic**

EXPAND TAVR

THE EARLY TAVR TRIAL

What Does this Mean?

	PATIENT AGE	KEY CONSIDERATIONS
	~85 years old	Life Expectancy
	~65 years old	Exercise Capacity
	Need to Avoid Valve-in-Valve	**Need More "Normal" Hemodynamics**

Otto, et al. ACC/AHA Guideline, JACC,2021, 77, e25-197 Bagur R, et al. Heart. 2017;103:1756-1759
Carroll, et al STS ACC TVT Registry JACC

Today's TAVR's Need to Address the Needs of Younger as well as Older Patients

Current Products Fall Short in Two Critical Areas:



ANTERIS

ADAPT for life

ADAPT ®

+ DurAVR™

+ ComASUR™

A completely new class of product in the TAVR space that demonstrates superior clinical results

DurAVR™ Transcatheter Heart Valve System is unique at every level

DurAVR

Single-Piece Aortic Valve



- Single Piece of Tissue
- Near Normal Hemodynamics
- Better Seal and Flow Reversal Ratio
- Improved Coronary Access

ADAPT

Anti-calcification Process



- Superior Anti-calcification
- Tissue Processing
- Proven Tissue Durability

ComASUR

Transfemoral Delivery System

- Allows for Precise Placement
- Alignment with the Native Aortic Valve's Position

In partnership with our world-renowned Medical Advisory Board, we have created a new integrated TAVR system to improve exercise capacity, quality of life, maximize durability and optimize future 'valve-in-valve' interventions

DurAVR™ – A More “Human Like” Valve

A new class of product

- **Opens wider (45%)**
  Restoring pre-disease hemodynamics
- Designed to be **anatomically correct** and provides a **better seal and flow reversal ratio**
- Single piece design provides **greater structural integrity and durability**

DurAVR™ THV IS NOT AVAILABLE FOR SALE, FOR CLINICAL INVESTIGATIONAL USE ONLY.

DurAVR™ Shaped to Perform like Native Aortic Valve

Optimizes flow dynamics, restoring hemodynamic performance



Single Piece Three Piece



Graphical representation of the 3D single-piece geometry of DurAVR™ THV (left), and standard balloon-expandable TAVI devices (right).

VD 2004 (PMID: 15473482)

DurAVR™ THV IS NOT AVAILABLE FOR SALE, FOR CLINICAL INVESTIGATIONAL USE ONLY.

- ✓ Compelling results from recent FIH study
- ✓ Robust data supporting durability

DurAVR™ THV IS NOT AVAILABLE FOR SALE, FOR CLINICAL INVESTIGATIONAL USE ONLY.

Exceptional Hemodynamic Results at 30 Days in Balloon Expandable Platform

Mean annulus size: 22.95 mm

Mean Pressure Gradient (MPG)
(n=13)



Doppler Velocity Index (DVI)
(n=13)



Indexed: AVA index, is calculated by dividing the aortic valve area (AVA) by the patient's body surface area (BSA).
DurAVR™ THV IS NOT AVAILABLE FOR SALE, FOR CLINICAL INVESTIGATIONAL USE ONLY.

Exceptional Hemodynamic Results at 30 Days in Balloon Expandable Platform

Mean annulus size: 22.95 mm

Effective Orifice Area
(n=13)



Effective Orifice Area Indexed
(n=13)



Indexed: AVA index, is calculated by dividing the aortic valve area (AVA) by the patient's body surface area (BSA).
DurAVR™ THV IS NOT AVAILABLE FOR SALE, FOR CLINICAL INVESTIGATIONAL USE ONLY.

Continued QoL Improvement at 1 year from baseline and 30 day results

1-Year 6-Minute Walk Test



DurAVR™: First AVR Shown to Restore Normal Aortic Flow

Normal Valve Flow vs DurAVR: *No Significant Difference in Flow (p=0.45)*

Healthy Aortic Valve



Flow Displacement (FD) = 12%
Flow Reversal Ratio (FRR) = 0%

Post DurAVR THV



Flow Displacement (FD) = 14%
Flow Reversal Ratio (FRR) = 4%

Impaired Aortic Flow

Severe AS
FD = 46%
FRR = 23%



Edwards' Sapien 3
FD = 48%
FRR = 35%



Medtronic's Evolut R
FD = 25%
FRR = 4%



Edward's CEP Magna Ease
FD = 27%
FRR = 30%



Severe AS

Normal Valve Flow vs TAVR: *p<0.05*

Normal Valve Flow vs SAVR: *p<0.001*

DurAVR™ THV IS NOT AVAILABLE FOR SALE, FOR CLINICAL INVESTIGATIONAL USE ONLY.

Biomimetic performance is needed for a restorative effect

Tomorrow's patients are increasingly younger and need restorative therapy to return to a pre-disease quality and length of life

Bioprosthetic Valve

*Competitor valves **look like nature** but have turbulent blood flow performance*

Sapien 3

Evolut



48% Flow Displacement
35% Flow Reversal Ratio



25% Flow Displacement
4% Flow Reversal Ratio

Turbulent flow treats symptoms of severe AS disease

Biomimetic Valve

*DurAVR **works like nature** with natural blood flow performance*

Healthy valve performance comparator





12% Flow Displacement
0% Flow Reversal Ratio



DurAVR



14% Flow Displacement
4% Flow Reversal Ratio

Native like performance addresses underlying affects of AS disease

DurAVR™ Demonstrates Superior EOA and MPG

21mm round fixture



Sapien Hydrodynamics

EOA: 2.30 mm2
Gradient: 8.8 mmHg



DurAVR Hydrodynamics

EOA: 2.83 mm2
Gradient: 5.9 mmHg



Evolut Hydrodynamics

EOA: 2.41 mm2
Gradient: 8.3 mmHg

Data on File. Courtesy of Janarthanan Sathananthan BHB MBChB MPH FRACP, University of British Columbia Centre of Cardiovascular Innovation, Vancouver General and St. Paul's Hospital.

DurAVR™ THV IS NOT AVAILABLE FOR SALE, FOR CLINICAL INVESTIGATIONAL USE ONLY.

Early Feasibility Study is on track for completion in Q2 and presentation at TCT in Q3

Dec 22 | Feb | Mar | May | Jun | Jul | Sep

- Preliminary Approval ✓
- Full Approval ✓
- Ethics Approvals (all sites)
- Site Budget Approvals
- Reimbursement
- Site Initiation Visits
- All Patients Enrolled
- 30 Day Follow Up
- Data Presented

Set up at all 7 sites progressing according to expectations – 3 SIV already scheduled for early April

DurAVR™ FDA Early Feasibility Study

Objective	Safety and Feasibility of DurAVR™ THV
Study Design	Single Arm Clinical Trial
N (patients/sites)	15 patients Up to 7 sites (Cleveland Clinic, Columbia Presbyterian, Montefiore, U. of Michigan, Abbott Northwestern, Houston Methodist, Tucson Medical Center)
Population	Native severe AS , **all surgical risk profiles**
Safety Endpoints	All-cause mortality or disabling stroke at 30 days (primary) VARC 3 (secondary)
Efficacy Endpoints	Technical Success Device Success including Hemodynamic Performance
Novel Parameter Assessment	Laminar Flow, LV remodeling, Exercise hemodynamics
Follow Up	10 years

Key account focus enables self funding commercial rollout upon launch

- Anteris anticipates up to 5% (USD 250-300 million) market share in the first 12 months post launch based on currently proven clinical results (best in class)
- TAVR procedures continue to be concentrated in high volume centers.
- 65% volume comes from top 20% of centers
- Anteris is well covered in these centers currently via its Medical Advisory Board physicians.
- Regulatory approval (clinical trials) and early commercialization costs are within the scope of our capital management strategy.
- **5% share in US = 50% share in top 10 centers or 25% share in top 35 centers**

US facilities validated and online

Anteris Institutional Partnerships

ADAPT for life

Partnering to Define a New Paradigm in Aortic Valve Science

Cardiovascular Research Foundation®

CHU Hôpitaux de Bordeaux

Cleveland Clinic

CLINIQUE Pasteur TOULOUSE

Columbia University Medical Center

Erasmus MC University Medical Center Rotterdam

HOUSTON Methodist LEADING MEDICINE

Karolinska Institutet

Minneapolis Heart Institute

Allina Health ABBOTT NORTHWESTERN HOSPITAL

Montefiore HEALTH SYSTEM

NHS Guy's and St Thomas' NHS Foundation Trust

ST. PAUL'S HOSPITAL PROVIDENCE HEALTH CARE

universitäts klinikum bonn

HEALTH SYSTEM UNIVERSITY OF MICHIGAN

UZ LEUVEN

Washington University in St. Louis SCHOOL OF MEDICINE

Yale Cardiovascular Research Center

Anteris Has Addressed Unmet Medical Needs With A New Class Of Product



By combining….

- Tissue science (ADAPT®)
- Valve design (DurAVR™)
- Physician developed delivery system (ComASUR™)

Anteris has created a more "human like" aortic valve replacement with results that reflect pre-disease states

DurAVR™ THV IS NOT AVAILABLE FOR SALE, FOR CLINICAL INVESTIGATIONAL USE ONLY.